// App-Quantinova.ai

: Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer

Researchers

Presenter

  • G.N.Hortobagyi

Principal Investigators

  • H.A.Burris

  • Y.S.Yap

  • G.S.Sonke

  • S.Paluch-Shimon

  • M.Campone

  • K.Petrakova

  • K.L.Blackwell

  • E.P.Winer

  • W.Janni

  • S.Verma

  • P.Conte

  • C.L.Arteaga

  • D.A.Cameron

  • S.Mondal

  • M.Miller

  • M.Elmeliegy

  • C.Germa

  • J.OShaughnessy

Medical Centers

  • Department of Bioinformatics, The University of Texas MD Anderson Cancer Center, Houston, TX

  • Institute of Oncology, Davidoff Center, Rabin Medical Center, Tel Aviv University, Petah Tikva, Israel

  • Sarah Cannon Research Institute, Nashville, TN

  • Department of Medical Oncology, National Cancer Centre Singapore, Singapore, Singapore

  • Netherlands Cancer Institute and BOOG Study Center, Amsterdam, Netherlands

  • Division of Hematology, Chaim Sheba Medical Center, Ramat Gan, Israel

  • Department of Medical Oncology, Institut de Cancérologie de l’Ouest/René Gauducheau, Saint‐Herblain, France

  • Department of Comprehensive Cancer Care, Masaryk Memorial Cancer Institute, Brno, Czech Republic

  • Internal Medicine, Duke University Medical Center, Durham, NC

  • Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA

  • Department of Urology, University of Ulm, Ulm, Germany

  • Department of Radiation Oncology, Tom Baker Cancer Centre, University of Calgary, Calgary, AB, Canada

  • Department of Surgery, Oncology and Gastroenterology and Division of Medical Oncology; University of Padua and Istituto Oncologico Veneto, IRCCS, Padua, Italy

  • Department of Medicine, Vanderbilt-Ingram Cancer Center, Nashville, USA

  • Edinburgh Cancer Research Center, University of Edinburgh, Edinburgh, United Kingdom

  • Department of Oncology, Novartis Pharmaceuticals Corporation, East Hanover, USA

  • Texas Oncology - Baylor Charles A. Sammons Cancer Center and The US Oncology Network, Dallas, TX

Locations

  • United States

  • Israel

  • Singapore

  • Netherlands

  • France

  • Czech Republic

  • Germany

  • Canada

  • Italy

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Breast cancer

Biomarkers

  • Human epidermal growth factor receptor 2

Drug/Treatment

  • Ribociclib

  • Letrozole

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

Phase

  • III

Study Id's

  • NCT01958021

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved